Edition:
United States

Precision Therapeutics Inc (AIPT.OQ)

AIPT.OQ on NASDAQ Stock Exchange Capital Market

1.18USD
1:19pm EDT
Change (% chg)

$-0.09 (-7.09%)
Prev Close
$1.27
Open
$1.21
Day's High
$1.21
Day's Low
$1.17
Volume
11,640
Avg. Vol
41,082
52-wk High
$2.50
52-wk Low
$0.81

Chart for

About

Precision Therapeutics Inc., formerly Skyline Medical Inc., is a medical device company that develops and manufactures The STREAMWAY System, a solution for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. The Company distributes these products to hospitals, surgical... (more)
No analyst recommendations are available for .

Overall

Beta: 1.05
Market Cap(Mil.): $15.17
Shares Outstanding(Mil.): 11.80
Dividend: --
Yield (%): --

Financials

  AIPT.OQ Industry Sector
P/E (TTM): -- 45.08 30.58
EPS (TTM): -1.16 -- --
ROI: -173.99 7.84 12.84
ROE: -177.55 11.57 15.02

BRIEF-Precision Therapeutics Q1 Loss Per Share $0.15

* PRECISION THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

May 15 2018

BRIEF-Precision Therapeutics Projects Meaningful Streamway System Sales In Europe In Second Half Of 2018

* PRECISION THERAPEUTICS PROJECTS MEANINGFUL STREAMWAY SYSTEM SALES IN EUROPE IN THE SECOND HALF OF 2018

May 10 2018

BRIEF-Precision Therapeutics Signs Letter Of Intent To Purchase Remainder Of Helomics Corporation Shares

* PRECISION THERAPEUTICS, INC. SIGNS LETTER OF INTENT TO PURCHASE REMAINDER OF HELOMICS CORPORATION SHARES

Apr 23 2018

BRIEF-Precision Therapeutics Q4 Loss Per Share $0.43

* PRECISION THERAPEUTICS REPORTS FISCAL YEAR 2017 FINANCIAL RESULTS

Apr 02 2018

BRIEF-Precision Therapeutics Announces Record Streamway System Sales In The First Three Months Of 2018

* PRECISION THERAPEUTICS ANNOUNCES RECORD STREAMWAY® SYSTEM SALES IN THE FIRST THREE MONTHS OF 2018

Mar 29 2018

BRIEF-Precision Therapeutics Unit Announces License Agreement With Cellbridge Inc

* PRECISION THERAPEUTICS SUBSIDIARY, TUMORGENESIS, ANNOUNCES LICENSE AGREEMENT WITH CELLBRIDGE INCORPORATED

Mar 21 2018

BRIEF-Precision Therapeutics Subsidiary, Tumorgenesis, Announces License Agreement With 48Hour Discovery

* PRECISION THERAPEUTICS SUBSIDIARY, TUMORGENESIS, ANNOUNCES LICENSE AGREEMENT WITH 48HOUR DISCOVERY Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

Mar 15 2018

BRIEF-Precision Therapeutics Unit, Tumorgenesis, Announces License Agreement With Syntarray LLC

* PRECISION THERAPEUTICS SUBSIDIARY, TUMORGENESIS, ANNOUNCES LICENSE AGREEMENT WITH SYNTARRAY, LLC

Mar 13 2018

Earnings vs. Estimates

No consensus analysis data available.